MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Intellia Therapeutics Inc. (NASDAQ:NTLA)*
Organization & Developments: Intellia
Parents
Intellia Therapeutics Inc. (NASDAQ:NTLA)*
Children
2016: Intellia Therapeutics Is A Buy - Intellia Therapeutics (NASDAQ:NTLA)
2018: Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study
2018: Intellia Therapeutics: Left Behind The Cas9 Excitement_seekingalpha.com
2020: Intellia Therapeutics: The Smallest Of The Big 3 CRISPR Companies Has Big Potential
2021: Intellia Expands Its In Vivo Advantage
2021: Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst _www.tipranks.com
2021: Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
2021: UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body
2021: With first-in-human trial results, Intellia shows the world that gene editing has arrived
2022: Intellia Therapeutics (NTLA) Investor Presentation - Slideshow_ seekingalpha.com
2022: Intellia Therapeutics (NTLA) Investor Presentation - Slideshow_seekingalpha.com
2022: Intellia Therapeutics: Top Speculative Trade In The Biotech Space_seekingalpha.com
2022: Intellia: In-Vivo Gene Editing Platform Continues To Deliver_ seekingalpha.com
2022: Intellia: Most Advanced In A Tough Field_ seekingalpha.com
2022: UPDATED: Intellia presents a promising snapshot of its first data for once-and-done in vivo CRISPR treatment for HAE
2023: As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide open'_fiercebiotech
2023: Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
2023: Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
2024: Doudna's Intellia, Zhang's Aera the latest gene editing biotechs to lay off staff
2024: Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
2024: Intellia data spark debate about CRISPR drug’s potential
2024: Intellia Therapeutics Announces Workforce Reduction Amid Strategic Shift
2024: Intellia Therapeutics Is On The Move
2024: Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
2024: Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
2024: Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
2025: Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
2025: For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat
2025: Gene editing stocks drop as Intellia announces layoffs
2025: Intellia culls 27% of staff as it takes ax to pipeline
2025: Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug
2025: Intellia pauses two late-stage CRISPR gene-editing trials due to safety concern
2025: Intellia plummets following severe adverse event in phase 3 nex-z trial | Seeking Alpha
2025: Intellia Therapeutics Announces Fourth Quarter and
2025: Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)
2025: Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)
2025: Intellia Therapeutics: Buying The Path To Commercialization_ seekingalpha.com
2025: Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year Investing.com
2025: Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
2025: Intellia: Heart Disease Safety Setback Triggers Selloff - Caution Advised
Jumps
*Key People: Intellia
Finance & Acquisitions: Intellia Therapeutics